Article
PLXDC1 May Serve As A Target For Combining Antiangiogenic Therapy and Immunotherapy In Gastric Adenocarcinoma
2021-08-24
Abstract excerpt
<title>Abstract</title> <p><bold>Introduction</bold> Based on the immunosuppression of traditional antiangiogenic agents in the treatment of tumors and the newly proposed concept of antiangiogenic therapy combined with immunotherapy, this paper will mainly explore the prospects of PLXDC1 in stomach adenocarcinoma<bold> </bold>(STAD) regarding antiangiogenic therapy and immunotherapy.<bold>Methods</bold> First, th...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 27562527-2f51-530d-ae96-7708016e4ba5
- DOI
- 10.21203/rs.3.rs-816727/v1
